Celgene Offers Results from Phase III Study of REVLIMID, Showed Improved Transfusion Independence
December 08, 2014 at 13:51 PM EST
Celgene Corporation (NASDAQ: CELG) today announced results from an international phase III study of REVLIMID® (lenalidomide) compared ...